Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05072080 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
A Phase 3 study of Chikungunya Virus, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,258
- Enrollment target
- 20
- Study locations
NCT05072080 is a Phase 3 study of Chikungunya Virus that has completed, run by Bavarian Nordic. The registered enrollment target is 3,258 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT05072080, a Phase 3 study of Chikungunya Virus, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,258 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CHIKV VLP/adjuvant
Study Locations (20)
Florida
- Jacksonville Center for Clinical Research - Jacksonville
- Accel Research Sites-DeLand Clinical Research Unit - Lake Mary
- Optimal Research, LLC - Melbourne
- Suncoast Research Associates, LLC - Miami
- Synexus Clinical Research US, Inc. - Pinellas Park
- Palm Beach Research Center - West Palm Beach
Kansas
- Johnson County ClinTrials - Lenexa
- Alliance for Multispecialty Research, LLC - Newton
- Alliance for Multispecialty Research - Wichita East - Wichita
Alabama
- Optimal Research, LLC - Huntsville
- Alliance for Multispecialty Research - Mobile - Mobile
California
- Velocity Clinical Research, Banning - Banning
- Optimal Research, LLC - San Diego
Illinois
- Synexus Clinical Research US, Inc. - Chicago
- Optimal Research LLC - Peoria
Arizona
- Alliance for Multispecialty Research, LLC - Tempe
Colorado
- Lynn Institute of the Rockies - Colorado Springs
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,258 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05072080
The ClinicalTrials.gov registry entry for NCT05072080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chikungunya Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05072080 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Kansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT05072080 about?
NCT05072080 is a clinical study titled "A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)". The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
What is the current status of trial NCT05072080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,258 participants. The study started on 2021-09-29. Estimated completion is 2023-04-03.
What conditions does trial NCT05072080 study?
This clinical trial studies the following conditions: Chikungunya Virus.
What interventions are being tested in trial NCT05072080?
The interventions under investigation include: Placebo (BIOLOGICAL), CHIKV VLP/adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05072080?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05072080 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.